SHZ · 300653.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Yantai Zhenghai Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Yantai Zhenghai Biotechnology Co., Ltd.’s forward annual dividend is CN¥0.28 per share, paid annual. The forward yield is 2.02% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Yantai Zhenghai Biotechnology Co., Ltd.’s next earnings report is currently expected on Apr 6, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Yantai Zhenghai Biotechnology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Yantai Zhenghai Biotechnology Co., Ltd., founded in 2003 and based in Yantai, China, specializes in the innovation, manufacturing, and commercialization of regenerative medical materials across China. The company's product offerings include a bone repair material, which is a partially deproteinized substance derived from calf cancellous bone after undergoing a series of processes like decellularization and degreasing. It also provides membranes for oral cavity repair, specifically designed to address shallow soft tissue defects in the mouth. Under the "Heal-All" brand, it supplies biomembranes used in neurosurgical procedures to mend defects of the cerebral dura mater. Additionally, the "Heal-Full" brand encompasses skin repair membranes developed for treating wounds within the dermal layer.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:03 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥97.42M+4.75% vs estimate |
| Q1 2025 | Apr 14, 2025 | CN¥0.06 | CN¥72.00M-22.58% vs estimate |
|---|
KEEP COMPARING
CN¥27.45-CN¥0.46 (-1.65%)
Zhejiang Wecome Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 31.75% below the high.
CN¥46.24-CN¥1.94 (-4.03%)
Shanghai Model Organisms Center, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.98% below the high.
CN¥5.82+CN¥0.02 (+0.34%)
Shandong Wohua Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.29% below the high.
CN¥11.48-CN¥0.26 (-2.21%)
Qingdao Vland Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.64% below the high.
CN¥7.54-CN¥0.19 (-2.46%)
Baolingbao Biology Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.5% below the high.
CN¥10.26-CN¥0.12 (-1.16%)
Guanhao Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.0% below the high.
CN¥14.60-CN¥0.26 (-1.75%)
Tibet AIM Pharm. Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.04% below the high.
CN¥13.58-CN¥0.04 (-0.29%)
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.88% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
